Mumbai co may become 1st in India to offer anti-retroviral drug for Covid
Rupali.Mukherjee@timesgroup.com
Mumbai 23.04.2020
In an indication of innovation in pharmaceuticals for Covid, Mumbai-based Glenmark may become the first company in India to offer an anti-retroviral, a class of drugs which has shown promise, and is being used as a potential treatment for the virus. Glenmark has developed antiretroviral (ARV) drug, Favipiravir, which has shown positive results globally, and has applied for regulatory approval for trials in India, sources told TOI.
Faviparir has demonstrated good results against influenza viruses, including those that are oseltamivir-resistant, and has been approved in Japan and China. Globally, it is either anti-malarial drug hydroxychloroquine, or anti-retrovirals/anti-virals like Favipiravir, Remdesivir and Lopinavir, that are increasingly being used for Covid treatment.
Japanese company Fujifilm sells the drug, Favipiravir, under the brand, Avigan, which has been approved in Japan since 2014 to treat influenza, and other viral strains that don’t respond to other therapies. The drug which was earlier used to treat Ebola, became off-patent last year, which implies generic versions can possibly be launched anywhere in the world. When contacted, Glenmark confirmed it has submitted its application to Drugs Controller General of India (DCGI) for marketing approval of Favipiravir.
Full report on www.toi.in
UNUSUAL SIGHT: Crows and a rat share food left by people on the roadside in New Delhi on Wednesday